Essential Requirements for Flying with Aciclovir
MHRA Approved Aciclovir for Travel
Aciclovir tablets are MHRA-licensed antiviral medications commonly prescribed for cold sore treatment. When travelling, passengers may carry personal supplies of aciclovir 400mg tablets or other strengths without restriction, provided they remain in original packaging. EverydayMeds supplies aciclovir in clearly labelled pharmacy packaging that meets airline requirements.
Airline Security Guidelines
UK airport security permits aciclovir tablets in both hand luggage and checked baggage. Tablet forms pose no liquid restrictions, making them convenient for travel. However, aciclovir cream (5%) must comply with the 100ml liquid rule if carried in hand luggage. Always keep a pharmacy receipt or prescription documentation as proof of legitimate medical use.
International Travel Considerations
Different countries may have varying regulations for importing prescription medications. Generally, personal supplies of aciclovir for up to 30 days are permitted without additional documentation. For longer trips, consider consulting the destination country's embassy or customs authority. Some countries require translated prescriptions or medical certificates for larger quantities.
Maintaining Treatment During Travel
Cold sore outbreaks can be triggered by travel stress, sun exposure, or disrupted sleep patterns common during flights. Pack sufficient aciclovir tablets for your entire trip plus extra days in case of delays. Flight cabin pressure and dehydration don't affect aciclovir's effectiveness, but maintaining your usual dosing schedule remains important for optimal treatment outcomes.
Available Treatment Options
EverydayMeds offers several aciclovir formulations suitable for travel, including aciclovir 400mg tablets and valaciclovir 500mg tablets as alternatives. Both are equally effective for cold sore treatment and available in travel-friendly packaging. Consider discussing with a pharmacist which formulation best suits your travel needs and treatment preferences.
